Skip to content

Public Proof Ledger · CLM-0018

FDA says CDER has seen significant growth in drug submissions using AI components across the product lifecycle.

Sourced factCurrentE5

Provenance

First verified: 2026-05-01
Last verified: 2026-08-08
Version: 1.0
Fingerprint: 8a9b964edc69e6ba
Change sensitivity: Medium
Correction state: No correction

Interpretation boundary

This is recorded as a sourced factual statement. Its scope should remain limited to what the cited source establishes.

Primary source

https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development

Related signals

SIG-2026-021 — FDA reports increasing use of AI across the drug-development lifecycle